Frankestin
1月前
MacroGenics now looks like a completely different company than it did a year ago.
Market cap around $230M… yet pro forma cash could reach $320–350M after the Bora transaction and Sagard royalty monetization.
They just transformed the balance sheet without dilution.
The GMP manufacturing divestiture alone should significantly reduce fixed costs:
-140 employees transferring to Bora
expensive FDA biologics infrastructure removed
lower facility, QA/QC, compliance and maintenance burden
transition toward a lean outsourced manufacturing model
At the same time, they retain access to clinical manufacturing through a supply agreement with Bora, preserving pipeline development flexibility.
Importantly, they didn’t sell the pipeline or core oncology IP.
They monetized non-core infrastructure and capped royalties instead. MacroGenics may have timed this perfectly: monetizing valuable U.S. biologics manufacturing infrastructure to a foreign buyer seeking an American footprint….
Now the setup becomes very interesting:
runway extended through 2028
no immediate financing overhang
multiple ADC catalysts ahead
MGC026 initial data mid-2026
MGC028 initial data H2 2026
MGC030 IND expected Q3 2026
Meanwhile, both ADC programs continue showing anti-tumor activity with no ILD observed so far, a major point for the ADC space.
The market still seems to value MacroGenics as if the pipeline were worth little more than zero.
iHub News
1月前
GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)May 12, 2026 11:08 AM
IH Market News MacroGenics agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals in a deal designed to strengthen its balance sheet and sharpen focus on its oncology pipeline. Key Investor Takeaways MacroGenics (NASDAQ:MGNX) will receive $122.5 million upfront from the sale of its GMP manufacturing business to Bora Pharmaceuticals. The transaction provides non-dilutive capital that management said will help fund pipeline development through key 2026 milestones. Bora Pharmaceuticals gains an FDA-approved biologics manufacturing facility with 11,000 liters of production capacity. MacroGenics plans to retain manufacturing access through a supply agreement tied to its internal oncology programs. The deal signals a strategic shift toward a more focused clinical-stage biotech model centered on antibody therapeutics. Why MGNX Stock Is in Focus MacroGenics (NASDAQ:MGNX) announced a definitive agreement to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals (USOTC:BORAY).Under the agreement, Bora will pay MacroGenics $122.5 million upfront before fees and expenses.The transaction includes the transfer of MacroGenics’ Rockville, Maryland headquarters site, its FDA-approved biologics manufacturing facility with 11,000 liters of capacity, and a warehouse facility in Frederick, Maryland.Approximately 140 MacroGenics employees are also expected to join Bora as part of the transition.The companies said the deal is expected to close in the third quarter of 2026, subject to customary closing conditions. Company Shifts Focus Toward Oncology Pipeline MacroGenics said the transaction aligns with strategic priorities announced last year to create a more focused organization centered on advancing its antibody-based cancer therapeutics pipeline.“This transaction supports that strategy by providing additional non-dilutive capital to accelerate our pipeline to key value inflection points in 2026 and beyond,” said Eric Risser.As part of the agreement, MacroGenics will maintain access to manufacturing support through a supply arrangement with Bora covering process development and drug substance production for its internal programs.For Bora, the acquisition expands its biologics manufacturing footprint in North America.“We view this acquisition as a key part of our strategy to expand Bora’s North American biologics operation under Bora Biologics,” said Bobby Sheng. Why This Matters for Investors The sale may reduce operational complexity for MacroGenics while strengthening its financial flexibility without issuing additional equity.For clinical-stage biotechnology companies, access to non-dilutive capital can be particularly important because it may limit shareholder dilution while funding pipeline development and upcoming clinical milestones.The transaction also suggests MacroGenics is prioritizing capital allocation toward drug development rather than maintaining internal manufacturing infrastructure.Investors may interpret the move as an effort to streamline operations around higher-value clinical and regulatory catalysts tied to the company’s oncology programs.At the same time, the long-term impact may depend on whether MacroGenics can successfully advance its therapeutic pipeline toward meaningful clinical data or partnership opportunities. What To Watch Next Investors will likely monitor the expected closing of the transaction in the third quarter of 2026 and any additional details regarding use of proceeds.Future updates tied to MacroGenics’ oncology pipeline, manufacturing transition execution, and upcoming clinical milestones could become key drivers for MGNX stock sentiment.Traders may also watch whether the company provides additional guidance around cash runway or development timelines following the completion of the sale.MacroGenics stock price Original: GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)
Frankestin
2月前
MacroGenics price target raised to $6 from $4 at Barclays
Ahrarara
Friends! 50,000 shares at only 3.60 — ah-ha-ra-ra-ra!
And remember: to move the market, you need blocks of 9,000… so today we’ve got special offers — 10,000 at 3.57, 9,000 at 3.56 — ah-ha-ra-ra-ra!
Frankestin
7月前
Forge Partnerships & Strengthen MacroGenics’ Financial Position * Gilead. In November 2025, Gilead licensed an additional MacroGenics preclinical program under a 2022 collaboration agreement, triggering a $25 million payment to MacroGenics. The licensed program leverages the Company's novel, proprietary platform with the goal of improving upon the safety and efficacy of traditional T-cell engagers. Under this collaboration, MacroGenics and Gilead are now advancing three programs, including MGD024, a clinical-stage CD123 × CD3 bispecific DART molecule, a preclinical TRIDENT(®) program and this latest preclinical DART program. The Company remains eligible to receive up to $1.6 billion in future milestones as well as royalties related to these three product candidates.
Frankestin
7月前
Sanofi. Sanofi continues to advance TZIELD(®) (teplizumab-mzwv), an antibody targeting CD3 that the Company sold in 2018 to a partner that was subsequently acquired by Sanofi S.A. (Sanofi). In August and September 2025, TZIELD was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom and by the National Medical Products Administration (NMPA) in China, respectively, triggering total milestone payments of $50 million, which are expected to be received during the fourth quarter. In October 2025, Sanofi announced that TZIELD had been accepted for expedited review in the U.S. for stage 3 type 1 diabetes through the FDA Commissioner’s National Priority Voucher pilot program. MacroGenics remains eligible to receive up to $330 million in additional milestones related to TZIELD.
Frankestin
1年前
Under the October 2022 collaboration, Gilead holds the exclusive option to license MGD024, exercisable at predefined decision points during the Phase 1 dose escalation study.
While study completion is expected in 2026–2027, these future license points allow for earlier decisions, typically based on meeting safety, tolerability, or early efficacy milestones.
It’s reasonable to expect Gilead could make a license decision before study end, contingent on achieving key Phase 1 data thresholds.
On May 15, 2025, the FDA approved Zynyz for anal canal squamous cell carcinoma (in combination with chemotherapy and as monotherapy) .
This approval likely triggered a regulatory milestone, resulting in a $15?million payment to MacroGenics (confirmed via Incyte's prior disclosures).
Frankestin
1年前
With the FDA approval of Zynyz for the treatment of Merkel cell carcinoma in March 2023, MacroGenics received a $15 million milestone payment. Subsequently, in July 2024, MacroGenics received an additional $100 million upon reaching development-related milestones for the drug. In total, MacroGenics has collected $215 million in milestone payments and remains eligible to receive up to $210 million in additional development and regulatory milestones, as well as $330 million in commercial milestones. Royalties on global sales of Zynyz range from 15% to 24%.
jgrabar
2年前
Attention Macrogenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Potential Claims on Your Behalf
MGNX | 3 days ago
Philadelphia, Pennsylvania--(Newsfile Corp. - November 7, 2024) - Grabar Law Office is actively investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders. If you have continuously held MacroGenics stock since before March 7, 2024, you may be entitled to seek corporate reforms, the return of funds to the company, and potentially receive a court-approved incentive award-all at no cost to you. Visit https://grabarlaw.com/the-latest/macrogenics-shareholder-investigation/ or email jgrabar@grabarlaw.com.